Blood Cancer News and Research

RSS

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc., a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma's ATIR™.

5 Jan 2011

Fundamental similarities in response to wasp infection and blood cancer development

Tiny parasitoid wasps can play an important role in controlling the populations of other insect species by laying their eggs inside the larvae of these species. A newly hatched wasp gradually eats the host alive and takes over its body.

4 Jan 2011

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA). These new centers join the 13 existing MMRC Member Institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.

23 Dec 2010

Researchers identify new regulator that play a critical role in B cell development

A team at the Institut de recherches cliniques de Montr-al led by Dr. Tarik M-r-y, President and Scientific Director of the institute and Director of the Hematopoiesis and Cancer research unit, will be publishing an important breakthrough in tomorrow's issue of Immunity, a scientific journal from the Cell Press group. The researchers identified a new regulator playing a critical role in the development B cells, which produce antibodies.

23 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

9 Dec 2010

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Abbott and Bristol-Myers Squibb Company today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.

7 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology, to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.

7 Dec 2010

No overall cancer risk in people who donate stem cells

American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

7 Dec 2010

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Ascenta Therapeutics, Inc. and The Leukemia & Lymphoma Society (LLS) today entered into an agreement whereby the LLS will support clinical development of Ascenta's oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML).

7 Dec 2010

Research reveals new standard treatment options for various forms of lymphoma

The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease.

6 Dec 2010

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

6 Dec 2010

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center.

25 Nov 2010

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Lotsa Helping Hands, the leading provider of a web-based caregiving coordination service, today announces a new feature that connects its community members to trusted resources from many of the nation's leading healthcare nonprofit organizations.

20 Nov 2010

New discovery can develop diagnostic test to identify gene mutation in AML

Decoding the DNA of a woman who died of acute myeloid leukemia (AML) has led researchers at Washington University School of Medicine in St. Louis to a gene that they found to be commonly altered in many patients who died quickly of the disease.

11 Nov 2010

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010

Blood Cancer News and Research

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Fundamental similarities in response to wasp infection and blood cancer development

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

Researchers identify new regulator that play a critical role in B cell development

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

John Theurer Cancer Center presents research findings at ASH meeting

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

No overall cancer risk in people who donate stem cells

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Research reveals new standard treatment options for various forms of lymphoma

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

New discovery can develop diagnostic test to identify gene mutation in AML

Research on AID enzyme could improve therapy for lymphoma, leukemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News